LONDON-- GlaxoSmithKline PLC (GSK.LN) Monday said it submitted sirukumab, a rheumatoid arthritis treatment it is developing with fellow drug company Janssen Biologics Ireland, for approval by the European Medicines Agency.

Glaxo shares at 1138 GMT, down 10 pence, or 0.7%, at 1,589 pence valuing the company at GBP77.45 billion.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

(END) Dow Jones Newswires

September 12, 2016 07:55 ET (11:55 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.